RxDoctor Payments Data

Morales Brown, MD

Psychiatry · Utica, NYNPI 1679775266

Payments from drug & device makers

$3,069in general payments, 2019–2025

Across 173 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$713
  • AbbVie$496
  • Johnson & Johnson$373
  • Sunovion Pharmaceuticals Inc.$280
  • Lundbeck LLC$229
  • Alkermes, Inc.$228
  • plus $749 from 9 others

What the payments were for

  • Food & beverage$2,95596%
  • Education$1144%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,069 in reported general payments places this provider in the 85th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$37,303
Medicare patients
113
Services billed
453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate25$209,154
Invega SustennaPaliperidone Palmitate60$199,968
RexultiBrexpiprazole93$165,366
Abilify MaintenaAripiprazole26$69,716
Tasimelteon12$68,458
TrintellixVortioxetine Hydrobromide90$51,366
VraylarCariprazine Hcl27$40,768
Aripiprazole224$19,594
CaplytaLumateperone Tosylate12$18,573
Divalproex Sodium ErDivalproex Sodium180$14,535
Clozapine OdtClozapine12$12,994
Quetiapine Fumarate389$11,812
Lurasidone Hcl38$11,384
Olanzapine207$11,300
Clozapine77$9,539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna, Risperdal Consta$373$416,74097 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$713$235,082119 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$103$51,36690 claims
AbbVieVraylar$496$40,76827 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$52$18,57312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Utica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →